EODData

MEMBERSHIP REGISTER LOG IN

FRA, RGO: Regeneron Pharmaceuticals Inc

14 Aug 2026
LAST:

694.3

CHANGE:
 6.00		OPEN:
694.3		HIGH:
694.3		ASK:
0.0		VOLUME:
7
CHG(%):
0.87		PREV:
688.3		LOW:
694.3		BID:
0.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
14 Aug 26694.3694.3694.3694.37
13 Aug 26688.3688.3688.3688.37
12 Aug 26688.3688.3688.3688.37
07 Aug 26664.5664.5664.5664.520
06 Aug 26663.5663.5663.5663.50
05 Aug 26655.9655.9655.9655.920
04 Aug 26656.8656.8656.8656.822
03 Aug 26672.9672.9660.2660.822
31 Jul 26634.0650.1634.0650.127
30 Jul 26600.5616.0600.5616.0140

PROFILE

Name:Regeneron Pharmaceuticals Inc
About:Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
Sector:Healthcare
Industry:Biotechnology
Address:777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
Website:https://www.regeneron.com
ISIN:US75886F1075
LEI:549300RCBFWIRX3HYQ56

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:18.45 
Forward P/E:14.82 
PEG Ratio:14.82 
Price to Sales:4.83 
Price to Book:2.56 
Profit Margin:0.32 
Operating Margin:0.30 
Return on Assets:0.06 
Return on Equity:0.15 
DivYield:0.00 
Div/Share:1.76 
Revenue:12.104B 
EBITDA:4.283B 
Shares:104.17M 
Market Cap:72.325B 

TECHNICAL INDICATORS

MA5:679.782.1%
MA10:663.854.6%
MA20:623.7111.3%
MA50:577.0320.3%
MA100:595.0316.7%
MA200:609.3313.9%
STO9:100.00 
STO14:100.00 
RSI14:96.46 
MTM14:125.00
ROC14:0.22 
ATR:11.64 
Week High:694.300.0%
Week Low:664.504.5%
Month High:694.300.0%
Month Low:565.7013.9%
Year High:700.200.8%
Year Low:471.7047.2%
Volatility:13.20 

RECENT DIVIDENDS

Date Amount
20 Nov 2025$0.76
18 Aug 2025$0.75
20 May 2025$0.88
20 Feb 2025$0.85
11 Aug 2022$0.00
15 Jul 2021$0.00